{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:36:35Z","timestamp":1791178595619,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[1998,12,1]],"date-time":"1998-12-01T00:00:00Z","timestamp":912470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":7696,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1998,12]]},"DOI":"10.1023\/a:1008441416790","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T09:30:06Z","timestamp":1040549406000},"page":"1315-1322","source":"Crossref","is-referenced-by-count":42,"title":["Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days"],"prefix":"10.1016","volume":"9","author":[{"given":"C.","family":"Sessa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Minoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Borner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Renard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u2019lncalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008441416790_bb0010","first-page":"2581","article-title":"Preclinical antitumour evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): An orally active platinum drug","volume":"53","author":"Kelland","year":"1993","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008441416790_bb0015","first-page":"4118","article-title":"Schedule dependency of orally administered Bis-acetato-dichlorocyclohexylamine-platinum (IV) (JM216) in vivo","volume":"54","author":"Mc Keage","year":"1994","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008441416790_bb0020","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/bjc.1993.182","article-title":"Lack of nephrotoxicity of oral ammine\/amine platinum (IV) dicarboxylate complexes in rodents","volume":"67","author":"Mc Keage","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008441416790_bb0025","first-page":"629","article-title":"Lack of neurotoxicity of oral bis acetato amine dichloro cyclohexylamine platinum (IV) (JM216) in comparison to cisplatin and tetraplatin in the rat","volume":"54","author":"Mc Keage","year":"1994","journal-title":"Cancer Res"},{"key":"10.1023\/A:1008441416790_bb0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00685793","article-title":"A phase I and pharmacology study of an oral platinum complex JM216: Dose-dependent pharmacokinetics with single-dose administration","volume":"36","author":"Mc Keage","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008441416790_bb0035","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.1997.15.7.2691","article-title":"Phase I and pharmacokinetic study of an oral platinum complex given daily for five days in patients with cancer","volume":"15","author":"Mc Keage","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008441416790_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1023\/A:1008441416790_bb0045","first-page":"81","article-title":"Determination of platinum in biological fluids by ICP-mass spectrometry","volume":"12","author":"Casetta","year":"1991","journal-title":"Atom Spectrom"},{"key":"10.1023\/A:1008441416790_bb0050","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0010-468X(83)90006-5","article-title":"NL-FIT: A microcomputer program for non-linear fitting","volume":"16","author":"Sacchi-Landriani","year":"1983","journal-title":"Comput Programs Biomed"},{"key":"10.1023\/A:1008441416790_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s002800050464","article-title":"Biotransformation of the platinum drug JM216 following oral administration to cancer patients","volume":"38","author":"Raynaud","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008441416790_bb0060","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1023\/A:1008245709924","article-title":"Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation","volume":"8","author":"Judson","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008441416790_bb0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s002800050624","article-title":"Combination chemotherapy involving orally administered etoposide and JM216 in murine tumor models","volume":"40","author":"Rose","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008441416790_bb0070","first-page":"17","article-title":"A Phase I study of oral uracil\/ftorafur (UFT) plus leucovorin (LV) and oral JM216 each given over 14 days every 28 days","author":"Ratain","year":"1998","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419616601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419616601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/9\/12\/1315\/19481541\/9-12-1315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T20:26:50Z","timestamp":1582230410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419616601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["S0923753419616601"],"URL":"https:\/\/doi.org\/10.1023\/a:1008441416790","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}